专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3004071A1 CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS 无效转让
标题翻译：维生素MZ氧化还原酶的羧化酶ZUR BEHANDLUNG VON ERKRANKUNGEN
公开(公告)号：EP3004071A1
公开(公告)日：2016-04-13
申请号：EP14732802.5
申请日：2014-05-30
申请人： Edison Pharmaceuticals, Inc.
发明人： HINMAN, Andrew, W. , KHEIFETS, Viktoria , SHRADER, William, D.
IPC分类号： C07D307/33 , C07C69/732 , C07C69/95 , C07C235/30 , C07C235/78 , A61K31/215 , A61K31/341 , A61K31/16
CPC分类号： C07D307/33 , C07C66/00 , C07C69/732 , C07C69/95 , C07C235/78 , C07C2601/02 , C07C2601/10 , C07C2601/16
摘要： Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compounds are quinone or naphthoquinone compounds with carboxylic acid or carboxylic acid derivative substituents.
摘要翻译：本文公开了使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经退行性疾病和衰老疾病）或用于调节一种或多种能量生物标志物，使一种或多种能量生物标志物正常化的化合物和方法，或增强一种或多种能量生物标志物，其中所述化合物是具有羧酸或羧酸衍生物取代基的醌或萘醌化合物。

2. 发明公开

EP2892516A1 QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS 审中-公开
标题翻译： CHINONDERIVATE ZUR VERWENDUNG BEI DER REGULIERUNG DES REDOXSTATUS VON PERSONEN
公开(公告)号：EP2892516A1
公开(公告)日：2015-07-15
申请号：EP13765880.3
申请日：2013-09-06
申请人： Edison Pharmaceuticals, Inc.
发明人： MILLER, Guy, M. , SHRADER, William, D. , KHEIFETS, Viktoria
IPC分类号： A61K31/045 , A61P39/06
CPC分类号： A61K31/122 , A61K31/05 , A61K31/198 , C07C66/00
摘要： Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: R1 and R2 are independently hydrogen, (C1-C6)alkyl or —O(C1-C6)alkyl; or R1 and R2 together represent —CH═CH—CH═CH—; R3 is (C1-C6)alkyl; X is —CH═CH— or —C≡C—; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the —X—(CH2)n— group; Y is —OR4, —CN, —C(=0)OR5, —C(=0)R5, or —C(=0)N(R6)2; R4 and R5 are independently selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(=0)-(C1-C6)alkyl, —C(=0)-(C1-C6)haloalkyl, —C(=0)-NH(C1-C6)alkyl, —C(=0)-N((C1-C6)alkyl)2, —C(=0)-NH2, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of —(C1-C6)alkyl, -0-(C1-C6)alkyl, —(C1-C6)haloalkyl, and halo; each R6 is independently hydrogen or —(C1-C6)alkyl; and M is —H, —C(0)—R7 or —C(0)0-R7, wherein R7 is —(C1-C6)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof.
摘要翻译：本文公开了使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经退行性疾病和衰老疾病）或用于调节一种或多种能量生物标志物，使一种或多种能量生物标志物正常化的化合物和方法，或增强一种或多种能量生物标志物，其中所述化合物是式I或式II的化合物：其中：R 1和R 2独立地是氢，（C 1 -C 6）烷基或-O（C 1 -C 6）烷基; 或者R1和R2一起表示-CH = CH-CH = CH-; R3是（C1-C6）烷基; X是-CH = CH-或-C≡C-; m为1-10; n为1-5; k为1-3，条件是当k为2或3的整数时，每个出现的-X-（CH 2）n - 基团，n独立地为1-5。 Y是-OR 4，-CN，-C（= O）OR 5，-C（= O）R 5或-C（= O）N（R 6）2; R4和R5独立地选自氢， - （C1-C6）烷基， - （C1-C6）卤代烷基，-C（= O） - （C1-C6）烷基，-C（= O）（C 1 -C 6）烷基，-C（= O）-NH（C 1 -C 6）烷基，-C（= O）-N（（C 1 -C 6）烷基）2，-C（= O）-NH 2，苯基，其中苯基可以任选被选自 - （C 1 -C 6）烷基，-O-（C 1 -C 6）烷基， - （C 1 -C 6）卤代烷基和卤素的取代基取代; 每个R 6独立地是氢或 - （C 1 -C 6）烷基; 并且M是-H，-C（O）-R7或-C（O）0-R7，其中R7是 - （C1-C6）烷基或苯基; 或立体异构体，立体异构体的混合物，药学上可接受的盐，结晶形式，非结晶形式，水合物或溶剂化物。

3. 发明公开

EP2344142A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS 有权转让
标题翻译： BEHANDLUNG VON PERVASIVENENTWICKLUNGSSTÖRUNGENMIT REDOX-AKTIVEN THERAPEUTIKA
公开(公告)号：EP2344142A1
公开(公告)日：2011-07-20
申请号：EP09792325.4
申请日：2009-09-08
申请人： Edison Pharmaceuticals, Inc.
发明人： MILLER, Guy, M. , KHEIFETS, Viktoria
IPC分类号： A61K31/05 , A61K31/122 , A61P25/00
CPC分类号： A61K31/122 , A23L33/10 , A23L33/40 , A23V2002/00 , A61K31/05 , C07C39/08 , C07C50/02 , C07C50/06
摘要： Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
摘要翻译：治疗或抑制普遍发育障碍（PDD）的方法包括：自闭症，阿斯伯格综合征，儿童崩解性障碍（CDD），雷蒂氏症和拒绝性PDD（PDD-NOS）或注意力缺陷/多动障碍（ADHD），包括向有需要的受试者施用治疗有效量的一种或更多的化合物。

4. 发明公开

EP2892515A1 BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS 审中-公开
标题翻译： BENZOCHINONDERIVATE ZUR BEHANDLUNG VON氧化应变片
公开(公告)号：EP2892515A1
公开(公告)日：2015-07-15
申请号：EP13762705.5
申请日：2013-09-06
申请人： Edison Pharmaceuticals, Inc.
发明人： SHRADER, William, D. , HINMAN, Andrew, W. , KHEIFETS, Viktoria
IPC分类号： A61K31/045 , A61K31/16 , A61K31/19 , A61K31/277 , C07C33/02 , C07C33/04 , C07C255/01 , C07C53/126 , C07C233/11 , A61P39/06
CPC分类号： A61K31/122 , A61K31/05 , A61K31/198 , C07C66/00
摘要： Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: R1 and R2 are independently hydrogen, (C1-C6)alkyl or —O(C1-C6)alkyl; or R1 and R2 together represent —CH═CH—CH═CH—; R3 is (C1-C6)alkyl; X is —CH═CH— or —C≡C—; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the —X—(CH2)n— group; Y is —OR4, —CN, —C(=0)OR5, —C(=0)R5, or —C(=0)N(R6)2; R4 and R5 are independently selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(=0)-(C1-C6)alkyl, —C(=0)-(C1-C6)haloalkyl, —C(=0)-NH(C1-C6)alkyl, —C(=0)-N((C1-C6)alkyl)2, —C(=0)-NH2, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of —(C1-C6)alkyl, -0-(C1-C6)alkyl, —(C1-C6)haloalkyl, and halo; each R6 is independently hydrogen or —(C1-C6)alkyl; and M is —H, —C(0)—R7 or —C(0)0-R7, wherein R7 is —(C1-C6)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof.
摘要翻译：本文公开了使用这些化合物治疗或抑制氧化应激障碍（包括线粒体病症，受损能量加工障碍，神经退行性疾病和衰老疾病）或用于调节一种或多种能量生物标志物，使一种或多种能量生物标志物正常化的化合物和方法，或增强一种或多种能量生物标志物，其中所述化合物是式I或式II的化合物：其中：R 1和R 2独立地是氢，（C 1 -C 6）烷基或-O（C 1 -C 6）烷基; 或者R1和R2一起表示-CH = CH-CH = CH-; R3是（C1-C6）烷基; X是-CH = CH-或-C≡C-; m为1-10; n为1-5; k为1-3，条件是当k为2或3的整数时，每个出现的-X-（CH 2）n - 基团，n独立地为1-5。 Y是-OR 4，-CN，-C（= O）OR 5，-C（= O）R 5或-C（= O）N（R 6）2; R4和R5独立地选自氢， - （C1-C6）烷基， - （C1-C6）卤代烷基，-C（= O） - （C1-C6）烷基，-C（= O）（C 1 -C 6）烷基，-C（= O）-NH（C 1 -C 6）烷基，-C（= O）-N（（C 1 -C 6）烷基）2，-C（= O）-NH 2，苯基，其中苯基可以任选被选自 - （C 1 -C 6）烷基，-O-（C 1 -C 6）烷基， - （C 1 -C 6）卤代烷基和卤素的取代基取代; 每个R 6独立地是氢或 - （C 1 -C 6）烷基; 并且M是-H，-C（O）-R 7或-C（O）O-R 7，其中R 7是 - （C 1 -C 6）烷基或苯基; 或立体异构体，立体异构体的混合物，药学上可接受的盐，结晶形式，非结晶形式，水合物或溶剂化物。

5. 发明公开

EP2470168A1 METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA 有权转让
标题翻译：方法预防和治疗脑缺血
公开(公告)号：EP2470168A1
公开(公告)日：2012-07-04
申请号：EP10747777.0
申请日：2010-08-24
申请人： Edison Pharmaceuticals, Inc.
发明人： MILLER, Guy, M. , KHEIFETS, Viktoria
IPC分类号： A61K31/122 , A61P25/28
CPC分类号： A61K31/122
摘要： The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I.
摘要翻译：本发明提供用于脑缺血，包括施用组合物，包含式I化合物相关的治疗，改善，或神经元损伤的症状的预防方法

6. 发明公开

EP2424494A1 FORMULATION OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES 审中-公开
标题翻译： ON EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN
公开(公告)号：EP2424494A1
公开(公告)日：2012-03-07
申请号：EP10715649.9
申请日：2010-04-27
申请人： Edison Pharmaceuticals, Inc.
发明人： MILLER, Guy, M. , SHRADER, William, D. , KHEIFETS, Viktoria
IPC分类号： A61K9/00 , A61K9/14 , A61K31/05 , A61K31/122 , A61P27/02 , A61P27/06 , A61P25/02 , A61P25/16 , A61P25/28
CPC分类号： A61K31/122 , A61K9/0048 , A61K9/0053 , A61K31/353 , A61K47/44
摘要： A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed.
摘要翻译：公开了包含眼睛有效量的一种或多种生育三烯酚醌，特别是α-生育三烯酚醌的制剂。还讨论了包含一种或多种生育三烯酚醌的制剂用于预防，减少，改善或治疗与神经退行性或创伤性病症相关的眼科疾病的用途。还讨论了用包含一种或多种生育三烯酚醌的制剂治疗或控制与神经变性疾病或创伤相关的眼部症状的方法。还讨论了用包含一种或多种生育三烯酚醌的制剂治疗或控制与线粒体肌病相关的眼部症状的方法。

7. 发明公开

EP2303309A2 TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC 审中-公开
标题翻译：线粒体疾病与促红细胞生成素的任何模拟物治疗
公开(公告)号：EP2303309A2
公开(公告)日：2011-04-06
申请号：EP09751496.2
申请日：2009-05-20
申请人： Edison Pharmaceuticals, Inc.
发明人： MILLER, Guy, M. , SHRADER, William, D. , KHEIFETS, Viktoria
IPC分类号： A61K38/18 , A61P25/00
CPC分类号： A61K38/1816
摘要： Methods of treating mitochondrial disorders that are not respiratory chain disorders using compositions comprising EPO mimetic compounds or compounds capable of increasing endogenous EPO levels or stimulating erythropoiesis are disclosed. Methods of treating Friedreich's ataxia, Leigh's syndrome, or other disorders by increasing the expression of frataxin with an EPO mimetic compound or a compound capable of increasing endogenous EPO levels or stimulating erythropoiesis are also disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式